|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five genetic polymorphisms of the RAAS (ACE, AGTR1, AGT, CMA, CYP11B2) were analyzed in all patients and the results of genetic analysis were correlated to severity of AS and LVH to determine the importance of the polymorphisms for LVH.
|
11275936 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
|
12640257 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
|
10440164 |
1999 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of IT genotype of ATG gene in patients with LVH was significantly (P<0.01) greater than that in normal controls or marginally (P=0.1) higher than that in patients without LVH.
|
10646957 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
1.The relationship between the angiotensinogen (AGT) T174M, angiotensin converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1) genetic markers and left ventricular hypertrophy was examined in normal subjects and those with aortic stenosis.2.
|
8800593 |
1996 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, neither ID ACE-gene polymorphism nor ATI-receptor gene and angiotensinogen gene polymorphism was associated with LVH.
|
11688760 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy.
|
17145981 |
2007 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of the AGT M235T gene but not ACE I/D gene is associated with greater LVMi and relative wall thickness, indicating more concentric LVH, in Chinese peritoneal dialysis patients.
|
12675870 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43).
|
12022239 |
2002 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The angiotensinogen T174M and M235T and the AT1-receptor A1166C polymorphisms were related to the change in LVH during antihypertensive treatment with an AT1-receptor antagonist; of these angiotensinogen T174M was the most powerful.
|
11910301 |
2002 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest an association of combined angiotensin I-converting enzyme gene I/D polymorphism genotypes, and angiotensinogen gene M235T polymorphism genotypes with left ventricular hypertrophy due to long-term athletic training.
|
11737220 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Exciting new discoveries concerned with polymorphisms of genes coding for angiotensin converting enzyme (ACE) and angiotensinogen suggest that Ang II may be genetically associated with increased risk for myocardial infarction, hypertension and left ventricular hypertrophy.
|
8583476 |
1995 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Low predictability of ACE genotype markers for LVH together with conflicting reports on the influence of RAS genetic variants on angiotensin II production suggests that the simple RAS paradigm may not apply for hypertension.
|
9433518 |
1997 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Untreated transgenic rats overexpressing the human renin and angiotensinogen genes (dTGR) feature hypertension and severe left ventricular hypertrophy with focal areas of necrosis, and die at age 7 weeks.
|
10880382 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
|
10805403 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was explore the relationship between plasma concentration of angiotensin II (Ang II), Adrenomedulin (ADM) and adrenotensin (ADT) in patients with hypertension and LVH.
|
31217886 |
2019 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy.
|
29196088 |
2018 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin II subtype 1 (AT1) receptor antagonist valsartan suppressed the elevated blood pressure completely and left ventricular hypertrophy incompletely, but did not affect the other phenotypes.
|
14620933 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the induction of human cardiac fibroblasts (HCF) and human umbilical vein endothelial cells (HUVEC) with the LVH mediator angiotensin II enabled us to investigate uremic LVH progression in vitro.
|
19094982 |
2009 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACE is responsible for the generation of angiotensin II, which is implicated in the development of left ventricular hypertrophy, an independent risk factor for morbidity and mortality in hypertension.
|
7820539 |
1994 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We challenged C57BL/6 adult male mice with an infusion of AngII (osmotic pumps; 2 mg/kg.day) to induce LVH.
|
30267750 |
2018 |